Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 I, 2000, Pages 1206-1212

  Aaron, Shawn D ^a   Ferris, Wendy ^b   Henry, Deborah A ^b   Speert, David P ^b   MacDonald, Noni E ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CLOXACILLIN; IMIPENEM; MEROPENEM; MINOCYCLINE; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BURKHOLDERIA CEPACIA; CLUSTER ANALYSIS; CYSTIC FIBROSIS; DNA DNA HYBRIDIZATION; DRUG EFFECT; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPUTUM CULTURE;

EID: 0034063849     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.4.9907147     Document Type: Article

References (25)

1. Laraya-Cuasay, L., M. Lipstein, and N. Huang. 1977. Pseudomonas cepacia in the respiratory flora of patients with cystic fibrosis (abstract). Pediatr. Pulmonol. 11:502.
2. Isles, A., I. Maclusky, and M. Corey. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210.
3. LiPuma, J. 1998. Burkholderia cepacia. Management issues and new insights. Clin. Chest Med. 19:473-486.
4. Vandamme, P., B. Holmes, M. Vancanneyt, T. Coenye, and B. Hoste. 1997. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst. Bacteriol. 47:1188-1200.
5. FitzSimmons, S. 1997. National Cystic Fibrosis Patient Registry. Cystic Fibrosis Foundation, Bethesda, MD.
6. Corey, M. 1999. Canadian Cystic Fibrosis Patient Registry. Canadian Cystic Fibrosis Foundation, Toronto, ON, Canada.
7. Lewin, L., P. Byard, and P. Davis. 1990. Effect of Pseudomonas cepacia colonization on survival and pulmonary function in cystic fibrosis patients. J. Clin. Epidemiol. 43:125-130.
8. Brown, P., S. Butler, and J. Nelson. 1993. Pseudomonas cepacia in adult cystic fibrosis: accelerated decline in lung function and increased mortality. Thorax 48:425-429.
9. Regelmann, W., G. Elliott, W. Warwick, and C. Clawson. 1990. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141:914-921.
10. Smith, A., C. Doershuk, D. Goldmann, E. Gore, and B. Hilman. 1999. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J. Pediatr. 134:413-421.
11. Grimwood, K., M. To, H. Rabin, and D. Woods. 1989. Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrob. Agents Chemother. 33:41-47.
12. Geers, T., and N. Baker. 1987. The effect of sublethal levels of antibiotics on the pathogenicity of Pseudomonas aeruginosa for tracheal tissue. J. Antimicrob. Chemother. 19:569-578.
13. Cantin, A., and D. Woods. 1993. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J. Clin. Invest. 91:38-45.
14. Hancock, R. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27:S93-S99.
15. Burns, J., C. Wadsworth, and J. Barry. 1989. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agent Chemother. 33:1247-1251.
16. Ferris, W., N. MacDonald, and A. MacKenzie. 1997. Multiple combination antibiotic testing for antibiotic synergy in multiresistant Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis (abstract). ICAAC Proceedings 1:E147.
17. Welch, D., M. Muszynski, C. Pai, M. Marcon, and M. Hribar. 1987. Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tract of patients with cystic fibrosis. J. Clin. Microbiol. 25:1730-1734.
18. Henry, D., M. Campbell, J. LiPuma, and D. Speert. 1997. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J. Clin. Microbiol. 35:614-619.
19. Mahenthiralingam, E., M. Campbell, D. Henry, and D. Speert. 1996. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J. Clin. Microbiol. 34:2914-2920.
20. Corey, M., and V. Farewell. 1996. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 143:1007-1017.
21. Marshall, B., and W. Samuelson. 1998. Basic therapies in cystic fibrosis: does standard therapy work? Clin. Chest Med. 19:487-504.
22. Grimwood, K., M. To, R. Semple, H. Rabin, P. Sokol, and D. Woods. 1993. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr. Pulmonol. 15:135-139.
23. Eisenberg, J., M. Pepe, J. Williams-Warren, M. Vasiliev, and B. Montgomery. 1997. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 111:955-962.
24. Henry, D., E. Mahenthiralingam, J. Bischof, M. Campbell, P. Vandamme and D. Speert. 1999. Epidemiology of Burkholderia cepacia in Canadian Cystic Fibrosis Patients. Program of the Sixth Meeting of the International Burkholderia cepacia Working Group, Banff, AB, Canada, April 1999.
25. LiPuma, J. J. 1999. Burkholderia cepacia Research Laboratory and Repository. Program of the Sixth Meeting of the International Burkholderia cepacia Working Group, Banff, AB, Canada, April 1999.